You are here: Industry Insights > miRNA

News List

Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc. prnasia
May 31, 2021
Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced on May 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc., an American new drug developer, for about 5.5 million U.S. dollars.
Liquid Biopsy Exosomal miRNA Panel Predicts Recurrence Following Surgery for Pancreatic Cancer firstwordpharma
May 26, 2021
A liquid biopsy exosomal microRNA (miRNA) panel can accurately predict cancer recurrence following surgery for pancreatic ductal adenocarcinoma, according to a study presented at Digestive Disease Week (DDW) 2021.
The world's first-in-class miRNA therapeutics to cure diabetes by pancreatic beta cell regeneration prnasia
May 07, 2021
Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., has selected its first technological investment target to expand its new bio business.
Nexturn Bio Inc. decided to invest in the development of a new drug pipeline for diabetes treatment using miRNA prnasia
May 07, 2021
Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug developer, as its first investment destination. RosVivo recently developed RSVI-301, a new drug pipeline that ...
Indian study may develop therapeutics for tongue cancer expresspharma
June 10, 2020
Identify a specific microRNA (miRNAs) called ‘miR-155’ that is over-expressed in tongue cancer.
Drug delivery using miRNA-enriched extracellular vesicles europeanpharmaceuticalreview
November 22, 2018
Researchers have developed a method of producing extracellular vesicles on a large scale to deliver drugs offering a standardised method of manufacture…